Nothing Special   »   [go: up one dir, main page]

WO2016140630A1 - An effervescent composition comprising levocetirizine and pseudoephedrine - Google Patents

An effervescent composition comprising levocetirizine and pseudoephedrine Download PDF

Info

Publication number
WO2016140630A1
WO2016140630A1 PCT/TR2015/000089 TR2015000089W WO2016140630A1 WO 2016140630 A1 WO2016140630 A1 WO 2016140630A1 TR 2015000089 W TR2015000089 W TR 2015000089W WO 2016140630 A1 WO2016140630 A1 WO 2016140630A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition according
acid
effervescent composition
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
PCT/TR2015/000089
Other languages
French (fr)
Inventor
Ersin Yildirim
Asiye Sezgin
Sevinç KAHRAMAN
Tolga Ramazan KARASU
Koray YILMAZ
Gökçek YAMAN
Derya AKSU
Original Assignee
PHARMACTIVE ILAÇ SANAYI VE TlCARET A. Ş.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PHARMACTIVE ILAÇ SANAYI VE TlCARET A. Ş. filed Critical PHARMACTIVE ILAÇ SANAYI VE TlCARET A. Ş.
Priority to PCT/TR2015/000089 priority Critical patent/WO2016140630A1/en
Publication of WO2016140630A1 publication Critical patent/WO2016140630A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Definitions

  • the present invention relates to the preparation of stable pharmaceutical compositions comprising levocetirizine and pseudoephedrine.
  • Levocetirizine which is an R-enantiomer of cetirizine is a piperazine derivative, potent and selective H1 receptor antagonist.
  • Levocetirizine, chemical name is (2- ⁇ 4 ⁇ [(R)-(4-Chlorophenyl) (phenyl)methyl]-1-piperazinyl ⁇ ethoxy)acetic acid.
  • Levocetirizine is an antihistaminic agent. It works by blocking a substance in the body called histamine. This helps to decrease allergy symptoms and hives. Levocetirizine is used to relieve runny nose; sneezing; and redness, itching, and tearing of the eyes caused by hay iever, urticaria, seasonal allergies, and allergies to other substances such as dust mites, animal dander, and mold. It is also used to treat symptoms of hives, including itching and rash.
  • Pseudoephedrine is a member of decongestant drugs. Pseudoephedrine and its pharmaceutically acceptable salts are well recognized by those skilled in the art as safe and effective nasa! and ocular decongestants.
  • Pseudoephedrine chemical name is (1S,2S)-2-( ethylamino)-1-phenyl-1-propanol.
  • Pseudoephedrine is a well known for shrinking swollen nasal mucous membranes. It reduces tissue hyperemia, edema, and nasal congestion commonly associated with colds or allergies. Other beneficial effects may include increasing the drainage of sinus secretions, and opening of obstructed Eustachian tubes. It is also indicated for vasomotor rhinitis, and as an adjunct to other agents in the optimum treatment of allergic rhinitis, croup, sinusitis, otitis media, and tracheobronchitis.
  • Pseudoephedrine can be used either as oral or topical decongestant.
  • the advantage of oral pseudoephedrine over topical nasal preparations is that it does not cause rebound congestion (rhinitis medicamentosa).
  • WO2011/146032 discloses effervescent composition of levocetirizine.
  • EP0811374 disclose a pharmaceutical composition comprising cetirizine and pseudoephedrine; US Patent 6,171 ,618 discloses a dosage form containing cetirizine as an immediate release component and pseudoephedrine as a controlled release component, a portion of the pseudoephedrine can be incorporated as an immediate release component.
  • EP 1404304 A1 A tablet comprising at least two distinct segments one segment of which comprises as active ingredient predominantly cetirizine and a second segment of which comprises as active ingredient predominantly pseudoephedrine.
  • WO2010/078541 describes a pharmaceutical composition comprising drug layer comprising drug particles comprising naproxen and cetirizine and another drug layer comprising pseudoephedrine, for treating symptoms of upper respiratory allergies, nasal congestion, and headache.
  • An effervescent pharmaceutical composition characterized in that it comprises:
  • present invention relates to an effervescent composition
  • an effervescent composition comprising:
  • levocetirizine means levocetirizine or pharmaceutically acceptable salt thereof.
  • pseudoephedrine means pseudoephedrine or pharmaceutically acceptable salt thereof.
  • Effervescent formulation of the present invention can be in powder, granule or tablet form. Effervescent formulation of the present invention is preferably in tablet form.
  • the composition of the present invention is in the form of an effervescent tablet intended to be dissolved or dispersed in water before administration and generally contains acid substances and carbonates or bicarbonates, which react rapidly in the presence of water releasing carbon dioxide.
  • the effervescent tablets comprise effervescent couples selected from, but not limited to, thermolabile gas generating agents such as sodium bicarbonate, sodium glycine carbonate, potassium bicarbonate, ammonium bicarbonate, sodium bisulfite, sodium metabisulfite, and an acid source such as citric acid, maleic acid or tartaric acid.
  • acid and base components are in the separate compartments.
  • compositions of this invention may be used in the treatment of vasomotor rhinitis. It can be reduced rhinitis and asthma symptoms and improved overall quality of life. It is indicated for the relief of nasal and non-nasal symptoms associated with seasonal or perennial allergic rhinitis in adults and children 12 years of age and older.
  • This invention can be used for the treatment of allergies, hay fever, pollen, dust, mold and tree allergies.
  • this invention is used to relieve allergy symptoms such as watery eyes, runny/stuffy nose, itching eyes/nose, and sneezing.
  • This invention may be used for the treatment of nasal congestion, sinus congestion, Eustachian tube congestion, and vasomotor rhinitis, and as an adjunct to other agents in the optimum treatment of allergic rhinitis, croup, sinusitis, otitis media, and tracheobronchitis.
  • This invention can include production method which is for increasing solubility. This method can be used in wet granulation.
  • An important subject of the present invention is to provide a formulation which has resistant against physical and enviromental conditions and also have a high bioavailability.
  • the present invention provides pharmaceutical formulations comprising active ingredients combination characterized by 1) good stability properties, 2 ⁇ controfiing the release of the active ingredient according to desired therapeutical needs, and finally 3) simple and also competitive manufacturing process.
  • levocetirizine may be effectively combined with pseudoephedrine, comparing with single activity of each of these and with an enhancement of the activity of pseudoephedrine and other compounds.
  • composition of the present invention may comprise one or more pharmaceutically acceptable excipient(s).
  • Pharmaceutically acceptable excipients comprise, but are not limited to, fillers, disintegrants, solvents, acid substance, base substance, binders, lubricants, glidants, sweeteners, aromatic agents, flavouring agents, preservatives, coloring agents, and the mixtures thereof.
  • Binders can be selected from the group, but are not limited to, methylcellulose, sodium carboxymethycellulose, calcium carboxymethycellulose, ethylcellulose, hydroxypropyl methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, silicified microcrystalline cellulose(SMCC), polyvinylpyrrolidone, gelatine, polyvinyl alcohol, acacia, tragacanth, guar, pectin, starch paste, potato starch, corn starch, wheat starch, pre-gelatinized starch, alginic acid, compressible sugar, liquid glucose, dextrates, dextrin, dextrose, ma!todextrin, guar gum, magnesium aluminium silicate, polymethacrylates, sorbitol, natural-synthetic gums and other materials known to one of ordinary skill in the art.
  • a mixture of binders may also be used.
  • Diluents may be water-soluble or water insoluble. Diluents can be selected from the group, but are not limited to, spray-dried or anhydrous lactose, sucrose, dextrose, starch, pre-geiatinized starch, mannitol, maltitol, sorbitol, xylitol, dextrin, cellulose derivatives including powdered cellulose, microcrystalline cellulose, dibasic calcium phosphate, tribasic calcium phosphate and calcium sulphate, kaolin, precipitated calcium carbonate, maltodextrin and other materials known to one of ordinary skill in the art. A mixture of diluents may also be used.
  • Lubricants can be selected from the group, but are not limited to, vegetable oils, such as hydrogenated vegetable oil or hydrogenated castor oil; polyethylene glycols, such as polyethylene glycol (PEG)-4000 and PEG-6000; stearic acid; derivatives of stearic acid, such as magnesium stearate, sodium stearate, calcium stearate, zinc stearate, glyceryl monostearate, glyceryl palmitostearate and sodium stearyl fumarate; mineral salts, such as talc; inorganic salts; organic salts, such as sodium benzoate, sodium acetate, sodium chloride and sodium oleate; and polyvinyl alcohols, microcrystalline cellulose, sodium lauryl sulphate, silica, colloidal silica, cornstarch, calcium silicate, magnesium silicate, silicon hydrogel and other materials known to one of ordinary skill in the art.A mixture of lubricants may also be used.
  • vegetable oils such as hydrogenated vegetable oil or hydrogenated
  • Gtidants can be selected from the group, but are not limited to, colloidal silicon dioxide, colloidal silica, cornstarch, talc, calcium silicate, magnesium silicate, magnesium trisiiicate, amorphous silica, colloidal silicon, silicon hydrogel, powdered cellulose, silicon dioxide, talc, tribasic calcium phosphate and other materials known to one of ordinary skill in the art. A mixture of glidants may also be used.
  • Flavoring agents including, but not limited to, black current, sodium chloride, strawberry, peppermint, menthol, artificial vanilla, cinnamon, various fruit flavors, natural aroma oils (such as peppermint oil, oil of wintergreen, clove bud oil, parsley oil, eucalyptus oil, lemon oil, orange oil), menthane, anethole, methyl salicylate, eucalyptol, methyl acetate, sage, 1-eugenol, oxanon, alpha-irisone, marjoram, lemon, orange, blackberry, propenyl guaetol acetyl, vanilla, timole, linalol, cinnamaldehyde glycerol acetal, N-substituted p-menthane-3-carboxamide and other materials known to one of ordinary skill in the art.
  • a mixture of flavoring agents may also be used.
  • Sweeteners including, but not limited to, sugars such as sucrose, glucose (corn syrup), invert sugar, fructose, and mixtures thereof; saccharin and its various salts such as sodium or calcium salt; cyclamic acid and its various salts such as sodium salt; the dipeptide sweeteners such as aspartame; dihydrochalcone; glycyrrhizin; Stevia rebaudiana (Stevioside); and sugar alcohols such as sorbitol, sorbitol syrup, D- tryptophan, monoammonium glycyrrhizinate, neohesperidin, dihydrochalcone, thaumatin, neotam, alitam, cyclamates,mannitol, xylitol, and the like.
  • a combination of sweeteners and flavoring agents can also be used.
  • Buffering agents can be selected from the group, but not limited to, potassium bicarbonate, citric acid, glycine, arginine, sodium acetate and sodium citrateand other materials known to one of ordinary skill in the art, and the mixtures thereof.
  • Acid substance can be selected from the group, but not limited to, ascorbic acid, citric acid, tartaric acid, malic acid, fumaric acid, adipic acid, lactic acid, oxalic acid, formic acid, benzene sulfonic add, benzoic acid, maleic acid, glutamic acid, succinic acid, aspartic acid, diatrizoic acid, acetic acid and acid anhydrides and acid salts thereof, and mixtures thereof.
  • the acidifying agent may also be an inorganic acid, such as hydrochloric acid, sulfuric acid, phosphoric acid, and nitric acid.
  • Base substance can be selected from the group, but not limited to, aluminum salts such as magnesium aluminum silicate; magnesium salts such as magnesium carbonate, magnesium trisiiicate, magnesium stearate; calcium salts such as calcium carbonate; bicarbonates such as calcium bicarbonate and sodium bicarbonate; phosphates such as monobasic calcium phosphate, dibasic calcium phosphate, dibasic sodium phosphate, tribasic sodium phosphate (TSP), dibasic potassium phosphate, tribasic potassium phosphate; metal hydroxides such as aluminum hydroxide, sodium hydroxide and magnesium hydroxide; metal oxides such as magnesium oxide; N-methyl glucami ' ne; arginine and salts thereof; amines such as monoethanolamine, diethanolamine, triethanolamine, and tris(hydroxymethyl)aminomethane (TRIS) and other materials known to one of ordinary skill in the art, and the mixtures thereof.
  • the pharmaceutical formulation are produced by one of the dry granulation, dry blending, direct compression,
  • the method proposed for production of the formulations of the present invention is preferably wet granulation method and it basically comprises the following steps;
  • the granulation solution to be used in the production of the formulations of the present invention comprise a pharmaceutically acceptable solvent in an effective amount and at least one binder.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to the preparation of effervescent compositions comprising a levocetirizine and pseudoephedrine.

Description

AN EFFERVESCENT COMPOSITION COMPRISING LEVOCETIRIZINE AND
PSEUDOEPHEDRINE
Field of invention
The present invention relates to the preparation of stable pharmaceutical compositions comprising levocetirizine and pseudoephedrine.
Background of the invention
Levocetirizine which is an R-enantiomer of cetirizine is a piperazine derivative, potent and selective H1 receptor antagonist. Levocetirizine, chemical name is (2-{4~[(R)-(4-Chlorophenyl) (phenyl)methyl]-1-piperazinyl}ethoxy)acetic acid.
Formula 1 : Levocetirizine
Figure imgf000002_0001
Levocetirizine is an antihistaminic agent. It works by blocking a substance in the body called histamine. This helps to decrease allergy symptoms and hives. Levocetirizine is used to relieve runny nose; sneezing; and redness, itching, and tearing of the eyes caused by hay iever, urticaria, seasonal allergies, and allergies to other substances such as dust mites, animal dander, and mold. It is also used to treat symptoms of hives, including itching and rash.
Pseudoephedrine is a member of decongestant drugs. Pseudoephedrine and its pharmaceutically acceptable salts are well recognized by those skilled in the art as safe and effective nasa! and ocular decongestants.
Pseudoephedrine, chemical name is (1S,2S)-2-( ethylamino)-1-phenyl-1-propanol.
Formula 2: Pseudoephedrine
Figure imgf000002_0002
Pseudoephedrine is a well known for shrinking swollen nasal mucous membranes. It reduces tissue hyperemia, edema, and nasal congestion commonly associated with colds or allergies. Other beneficial effects may include increasing the drainage of sinus secretions, and opening of obstructed Eustachian tubes. It is also indicated for vasomotor rhinitis, and as an adjunct to other agents in the optimum treatment of allergic rhinitis, croup, sinusitis, otitis media, and tracheobronchitis.
Pseudoephedrine can be used either as oral or topical decongestant. The advantage of oral pseudoephedrine over topical nasal preparations is that it does not cause rebound congestion (rhinitis medicamentosa).
WO2011/146032 discloses effervescent composition of levocetirizine.
EP0811374 disclose a pharmaceutical composition comprising cetirizine and pseudoephedrine; US Patent 6,171 ,618 discloses a dosage form containing cetirizine as an immediate release component and pseudoephedrine as a controlled release component, a portion of the pseudoephedrine can be incorporated as an immediate release component.
EP 1404304 A1 A tablet comprising at least two distinct segments one segment of which comprises as active ingredient predominantly cetirizine and a second segment of which comprises as active ingredient predominantly pseudoephedrine.
WO2010/078541 describes a pharmaceutical composition comprising drug layer comprising drug particles comprising naproxen and cetirizine and another drug layer comprising pseudoephedrine, for treating symptoms of upper respiratory allergies, nasal congestion, and headache.
Summary of the invention
An effervescent pharmaceutical composition, characterized in that it comprises:
a) pseudoephedrine or pharmaceutically acceptable salt thereof,
b) levocetirizine or pharmaceutically acceptable salt thereof,
in combination with at least one pharmaceutically acceptable excipient.
In a most preferred embodiment, present invention relates to an effervescent composition comprising:
a) 5-10 mg of levocetirizine,
b) 30-60 mg of pseudoephedrine,
c) citric acid,
d) sodium bicarbonate, and
e) at least one flavor. As used herein the term "levocetirizine" means levocetirizine or pharmaceutically acceptable salt thereof. As used herein the term "pseudoephedrine" means pseudoephedrine or pharmaceutically acceptable salt thereof.
Effervescent formulation of the present invention can be in powder, granule or tablet form. Effervescent formulation of the present invention is preferably in tablet form.
In a preferred embodiment, the composition of the present invention is in the form of an effervescent tablet intended to be dissolved or dispersed in water before administration and generally contains acid substances and carbonates or bicarbonates, which react rapidly in the presence of water releasing carbon dioxide. The effervescent tablets comprise effervescent couples selected from, but not limited to, thermolabile gas generating agents such as sodium bicarbonate, sodium glycine carbonate, potassium bicarbonate, ammonium bicarbonate, sodium bisulfite, sodium metabisulfite, and an acid source such as citric acid, maleic acid or tartaric acid.
Different carbonates, acids and buffers are used to attain good effervescence in short time and to obtain a clear solution, and to give maximum therapeutic effect in short time.
In one embodiment, in the compositions of the present invention, acid and base components are in the separate compartments.
Compositions of this invention may be used in the treatment of vasomotor rhinitis. It can be reduced rhinitis and asthma symptoms and improved overall quality of life. It is indicated for the relief of nasal and non-nasal symptoms associated with seasonal or perennial allergic rhinitis in adults and children 12 years of age and older.
This invention can be used for the treatment of allergies, hay fever, pollen, dust, mold and tree allergies. In addition, this invention is used to relieve allergy symptoms such as watery eyes, runny/stuffy nose, itching eyes/nose, and sneezing.
This invention may be used for the treatment of nasal congestion, sinus congestion, Eustachian tube congestion, and vasomotor rhinitis, and as an adjunct to other agents in the optimum treatment of allergic rhinitis, croup, sinusitis, otitis media, and tracheobronchitis.
In this present invention, it shows quick affect and efficiency.
This invention can include production method which is for increasing solubility. This method can be used in wet granulation.
An important subject of the present invention is to provide a formulation which has resistant against physical and enviromental conditions and also have a high bioavailability. The present invention provides pharmaceutical formulations comprising active ingredients combination characterized by 1) good stability properties, 2} controfiing the release of the active ingredient according to desired therapeutical needs, and finally 3) simple and also competitive manufacturing process.
We have now surprisingly found that levocetirizine may be effectively combined with pseudoephedrine, comparing with single activity of each of these and with an enhancement of the activity of pseudoephedrine and other compounds.
Pharmaceutical composition of the present invention may comprise one or more pharmaceutically acceptable excipient(s). Pharmaceutically acceptable excipients comprise, but are not limited to, fillers, disintegrants, solvents, acid substance, base substance, binders, lubricants, glidants, sweeteners, aromatic agents, flavouring agents, preservatives, coloring agents, and the mixtures thereof.
Binders can be selected from the group, but are not limited to, methylcellulose, sodium carboxymethycellulose, calcium carboxymethycellulose, ethylcellulose, hydroxypropyl methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, silicified microcrystalline cellulose(SMCC), polyvinylpyrrolidone, gelatine, polyvinyl alcohol, acacia, tragacanth, guar, pectin, starch paste, potato starch, corn starch, wheat starch, pre-gelatinized starch, alginic acid, compressible sugar, liquid glucose, dextrates, dextrin, dextrose, ma!todextrin, guar gum, magnesium aluminium silicate, polymethacrylates, sorbitol, natural-synthetic gums and other materials known to one of ordinary skill in the art. A mixture of binders may also be used.
Diluents may be water-soluble or water insoluble. Diluents can be selected from the group, but are not limited to, spray-dried or anhydrous lactose, sucrose, dextrose, starch, pre-geiatinized starch, mannitol, maltitol, sorbitol, xylitol, dextrin, cellulose derivatives including powdered cellulose, microcrystalline cellulose, dibasic calcium phosphate, tribasic calcium phosphate and calcium sulphate, kaolin, precipitated calcium carbonate, maltodextrin and other materials known to one of ordinary skill in the art. A mixture of diluents may also be used.
Lubricants can be selected from the group, but are not limited to, vegetable oils, such as hydrogenated vegetable oil or hydrogenated castor oil; polyethylene glycols, such as polyethylene glycol (PEG)-4000 and PEG-6000; stearic acid; derivatives of stearic acid, such as magnesium stearate, sodium stearate, calcium stearate, zinc stearate, glyceryl monostearate, glyceryl palmitostearate and sodium stearyl fumarate; mineral salts, such as talc; inorganic salts; organic salts, such as sodium benzoate, sodium acetate, sodium chloride and sodium oleate; and polyvinyl alcohols, microcrystalline cellulose, sodium lauryl sulphate, silica, colloidal silica, cornstarch, calcium silicate, magnesium silicate, silicon hydrogel and other materials known to one of ordinary skill in the art.A mixture of lubricants may also be used. Gtidants can be selected from the group, but are not limited to, colloidal silicon dioxide, colloidal silica, cornstarch, talc, calcium silicate, magnesium silicate, magnesium trisiiicate, amorphous silica, colloidal silicon, silicon hydrogel, powdered cellulose, silicon dioxide, talc, tribasic calcium phosphate and other materials known to one of ordinary skill in the art. A mixture of glidants may also be used.
Flavoring agents, including, but not limited to, black current, sodium chloride, strawberry, peppermint, menthol, artificial vanilla, cinnamon, various fruit flavors, natural aroma oils (such as peppermint oil, oil of wintergreen, clove bud oil, parsley oil, eucalyptus oil, lemon oil, orange oil), menthane, anethole, methyl salicylate, eucalyptol, methyl acetate, sage, 1-eugenol, oxanon, alpha-irisone, marjoram, lemon, orange, blackberry, propenyl guaetol acetyl, vanilla, timole, linalol, cinnamaldehyde glycerol acetal, N-substituted p-menthane-3-carboxamide and other materials known to one of ordinary skill in the art. A mixture of flavoring agents may also be used.
Sweeteners, including, but not limited to, sugars such as sucrose, glucose (corn syrup), invert sugar, fructose, and mixtures thereof; saccharin and its various salts such as sodium or calcium salt; cyclamic acid and its various salts such as sodium salt; the dipeptide sweeteners such as aspartame; dihydrochalcone; glycyrrhizin; Stevia rebaudiana (Stevioside); and sugar alcohols such as sorbitol, sorbitol syrup, D- tryptophan, monoammonium glycyrrhizinate, neohesperidin, dihydrochalcone, thaumatin, neotam, alitam, cyclamates,mannitol, xylitol, and the like. A combination of sweeteners and flavoring agents can also be used.
Buffering agents can be selected from the group, but not limited to, potassium bicarbonate, citric acid, glycine, arginine, sodium acetate and sodium citrateand other materials known to one of ordinary skill in the art, and the mixtures thereof.
Acid substance can be selected from the group, but not limited to, ascorbic acid, citric acid, tartaric acid, malic acid, fumaric acid, adipic acid, lactic acid, oxalic acid, formic acid, benzene sulfonic add, benzoic acid, maleic acid, glutamic acid, succinic acid, aspartic acid, diatrizoic acid, acetic acid and acid anhydrides and acid salts thereof, and mixtures thereof. The acidifying agent may also be an inorganic acid, such as hydrochloric acid, sulfuric acid, phosphoric acid, and nitric acid.
Base substance can be selected from the group, but not limited to, aluminum salts such as magnesium aluminum silicate; magnesium salts such as magnesium carbonate, magnesium trisiiicate, magnesium stearate; calcium salts such as calcium carbonate; bicarbonates such as calcium bicarbonate and sodium bicarbonate; phosphates such as monobasic calcium phosphate, dibasic calcium phosphate, dibasic sodium phosphate, tribasic sodium phosphate (TSP), dibasic potassium phosphate, tribasic potassium phosphate; metal hydroxides such as aluminum hydroxide, sodium hydroxide and magnesium hydroxide; metal oxides such as magnesium oxide; N-methyl glucami'ne; arginine and salts thereof; amines such as monoethanolamine, diethanolamine, triethanolamine, and tris(hydroxymethyl)aminomethane (TRIS) and other materials known to one of ordinary skill in the art, and the mixtures thereof. The pharmaceutical formulation are produced by one of the dry granulation, dry blending, direct compression, wet granulation methods.
The method proposed for production of the formulations of the present invention is preferably wet granulation method and it basically comprises the following steps;
a. Preparation of the granulation solution,
b. Granulation,
c. Drying and sieving,
d. Tablet compression.
The granulation solution to be used in the production of the formulations of the present invention comprise a pharmaceutically acceptable solvent in an effective amount and at least one binder.
Example 1
Figure imgf000007_0001
Example 2
Figure imgf000008_0001

Claims

Claims
1. An effervescent pharmaceutical composition, characterized in that it comprises;
a) levocetirizine or pharmaceutically acceptable salt thereof,
b) pseudoephedrine or pharmaceutically acceptable salt thereof,
in combination with at least one pharmaceutically acceptable excipient.
2. An effervescent composition according to claim 1 , wherein it comprises levocetirizine dihydrochloride in an effective amount.
3. An effervescent composition according to claim 1 , wherein it comprises pseudoephedrine hydrochloride in an effective amount.
4.An effervescent composition according to any one of the preceeding claims, it comprises at least one acid component selected from the group consisting of citric acid, tartaric acid, malic acid, fumaric acid, adipic acid, succinic acid, acid anhydrides and acid salts thereof, and mixtures thereof and at least one base component selected from the group consisting of carbonate salts, bicarbonate salts, phosphate salts, and mixtures thereof.
5. An effervescent composition according to claim 4, wherein acid component is citric acid and base component is sodium bicarbonate.
6. An effervescent composition according to claim 1 , wherein it comprises at least one sweetener agent.
7. An effervescent composition according to claim 6, wherein said sweetener is selected from a group comprising synthetic and natural sugars; sucrose, sucralose, saccharine, aspartame, acesulfame, thaumatin, dextrose, mannitol, maltitol, lactose, xylitol, isomalt, isomaltol, lactitol, eryhtrol, maltodextrin, alpha, beta and gamma cyclodextrins, dihydrochalcone, alitam, sorbitol, sodium cyclamate, miraculin, moneltin, steviocide and/or pharmaceutically acceptable salts thereof.
8. An effervescent composition according to claim 7, wherein said sweetener is sucralose and/or aspartame and/or acesulfame potassium.
9. An effervescent composition according to claim 1 , wherein it comprises at least one flavoring agent.
10. An effervescent composition according to claim 9,wherein flavoring agent is a combination of lemon and blackberry.
11. An effervescent composition according to any one of the preceeding claims, comprising: a) 5-10 mg of levocetirizine or pharmaceutically acceptable salt thereof, b) 30-60 mg of pseudoephedrine or pharmaceutically acceptable salt thereof,
c) citric acid,
d) sodium bicarbonate, and
e) at least one flavor.
12. An effervescent composition according to any one of the preceeding claims, comprising: a) 5 mg of levocetirizine or pharmaceutically acceptable salt thereof,
b) 60 mg of pseudoephedrine or pharmaceutically acceptable salt thereof,
c) citric acid,
d) sodium bicarbonate, and
e) at least one flavor.
13 An effervescent composition according to to any one of the preceeding claims, wherein it is in the form of powder, granule or tablet.
14. An effervescent composition according to claim 13, wherein it is a tablet.
15. An effervescent composition according to claim 14, wherein acid and base components are in the separate compartments.
16. An effervescent composition according to claim 15, wherein levocetirizin or pharmaceutical acceptable salt and pseudoefedrin or pharmaceutical acceptable salt and acid component are in the same compartment.
17. An effervescent composition according to any preceeding claims, for the manufacture of a medicament for preventing or treating disorders or conditions associated with rhinitis and asthma symptoms, allergies and symptoms, hay fever.sinus congestion, Eustachian tube congestion,croup, sinusitis, otitis media, tracheobronchitis, relief of nasal congestion, seasonal rhinitis, sneezing, rhinorrhea, nasal and ocular pruritus, redness of theeyes, tearing, sneezing.
PCT/TR2015/000089 2015-03-05 2015-03-05 An effervescent composition comprising levocetirizine and pseudoephedrine WO2016140630A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/TR2015/000089 WO2016140630A1 (en) 2015-03-05 2015-03-05 An effervescent composition comprising levocetirizine and pseudoephedrine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/TR2015/000089 WO2016140630A1 (en) 2015-03-05 2015-03-05 An effervescent composition comprising levocetirizine and pseudoephedrine

Publications (1)

Publication Number Publication Date
WO2016140630A1 true WO2016140630A1 (en) 2016-09-09

Family

ID=52815255

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2015/000089 WO2016140630A1 (en) 2015-03-05 2015-03-05 An effervescent composition comprising levocetirizine and pseudoephedrine

Country Status (1)

Country Link
WO (1) WO2016140630A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111214449A (en) * 2020-03-02 2020-06-02 广东彼迪药业有限公司 Cetirizine hydrochloride tablet and preparation method thereof

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003785A1 (en) * 1993-08-03 1995-02-09 Warner-Lambert Company Pleasant tasting effervescent cold/allergy medications
EP0811374A1 (en) 1996-05-29 1997-12-10 Pfizer Inc. Combination dosage form comprising cetirizine and pseudoephedrine
EP1404304A1 (en) 2001-06-28 2004-04-07 UCB Farchim S.A. Tablet comprising cetirizine and pseudoephedrine
US20070048375A1 (en) * 2003-12-19 2007-03-01 Wolfgang Wiehl Effervescent preparation of a basic medicinally active substance
WO2010078541A1 (en) 2009-01-05 2010-07-08 Mcneil-Ppc, Inc. Tablet containing coated particles of cetirizine, pseudoephedrine, and/or naproxen
WO2011146032A2 (en) 2010-05-18 2011-11-24 Mahmut Bilgic Effervescent formulations
WO2012064300A2 (en) * 2010-11-11 2012-05-18 Mahmut Bilgic Desloratadine granules
US20120301548A1 (en) * 2010-02-01 2012-11-29 Hanmi Science Co., Ltd Oral complex composition comprising pseudoephedrine and levocetirizine
WO2013058721A1 (en) * 2011-10-13 2013-04-25 Mahmut Bilgic Pharmaceutical granules and production method

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003785A1 (en) * 1993-08-03 1995-02-09 Warner-Lambert Company Pleasant tasting effervescent cold/allergy medications
EP0811374A1 (en) 1996-05-29 1997-12-10 Pfizer Inc. Combination dosage form comprising cetirizine and pseudoephedrine
US6171618B1 (en) 1996-05-29 2001-01-09 Pfizer Inc. Combination dosage form comprising cetirizine and pseudoephedrine
US20020012700A1 (en) * 1996-05-29 2002-01-31 Johnson Barbara A. Combination dosage form comprising cetirizine and pseudoephedrine
EP1404304A1 (en) 2001-06-28 2004-04-07 UCB Farchim S.A. Tablet comprising cetirizine and pseudoephedrine
US20070048375A1 (en) * 2003-12-19 2007-03-01 Wolfgang Wiehl Effervescent preparation of a basic medicinally active substance
WO2010078541A1 (en) 2009-01-05 2010-07-08 Mcneil-Ppc, Inc. Tablet containing coated particles of cetirizine, pseudoephedrine, and/or naproxen
US20120301548A1 (en) * 2010-02-01 2012-11-29 Hanmi Science Co., Ltd Oral complex composition comprising pseudoephedrine and levocetirizine
WO2011146032A2 (en) 2010-05-18 2011-11-24 Mahmut Bilgic Effervescent formulations
WO2012064300A2 (en) * 2010-11-11 2012-05-18 Mahmut Bilgic Desloratadine granules
WO2013058721A1 (en) * 2011-10-13 2013-04-25 Mahmut Bilgic Pharmaceutical granules and production method

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111214449A (en) * 2020-03-02 2020-06-02 广东彼迪药业有限公司 Cetirizine hydrochloride tablet and preparation method thereof
CN111214449B (en) * 2020-03-02 2021-09-07 广东彼迪药业有限公司 Cetirizine hydrochloride tablet and preparation method thereof

Similar Documents

Publication Publication Date Title
JP5683719B2 (en) Bepotastine composition
KR100653568B1 (en) Solid, quick dissolving cetirizine formulations
EP3013323B1 (en) Complex granule formulation having improved stability comprising levocetirizine and montelukast
EP3003384B1 (en) Oral solution comprising atomoxetine hydrochloride
KR20100086140A (en) A composition of fast dissolving tablets containing montelukast and it's manufacturing thereof
US10064820B2 (en) Antihistamine compositions, combinations, and use thereof
EP2563340A2 (en) Water soluble pharmaceutical composition
US20150072014A1 (en) Pharmaceutical Compositions of Sodium Picosulfate, Magnesium Oxide and Citric Acid
WO2016140630A1 (en) An effervescent composition comprising levocetirizine and pseudoephedrine
JP2018188377A (en) Pharmaceutical composition
EP4125824A1 (en) A sachet formulation comprising metformin and dapagliflozin
EP2571485B1 (en) Effervescent antihistamine formulations
EP2481395A1 (en) Sachet, effervescent tablet and dry syrup of otilonium
EP2959889A1 (en) Orally disintegrating formulations of loxoprofen
WO2015117987A1 (en) Effervescent formulations comprising ibuprofen and n-acetylcystein
US9265757B2 (en) Methods of administering antihistamines
KR20240136358A (en) Composition containing fexofenadine
AU2019306315B2 (en) Pharmaceutical composition in the form of a chewable tablet of diosmin or of a flavonoid moiety
WO2011139255A2 (en) Pharmaceutical compositions comprising cefetamet
JP2006342188A (en) Intraoral dissolution type or chewable solid internal medicine composition for treating rhinitis
KR20230022941A (en) Bioavailable sugar-based diclofenac formulation
US20050043296A1 (en) Compositions and methods for treating sexual dysfunction
TR201508678A2 (en) Pharmaceutical ingredients
KR20130076529A (en) Oral atomoxetine chewable tablet
WO2011139250A2 (en) Water dispersible formulation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15714982

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15714982

Country of ref document: EP

Kind code of ref document: A1